Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Transcatheter Arterial Chemoembolization Combined with Interferon-α is Safe and Effective for Patients with Hepatocellular Carcinoma after Curative Resection

  • Zuo, Chaohui (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Xia, Man (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Liu, Jingshi (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Qiu, Xiaoxin (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Lei, Xiong (Department of General Surgery, The Second Xiangya Hospital, Central South University) ;
  • Xu, Ruocai (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Liu, Hanchun (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Li, Jianliang (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Li, Yongguo (Department of General Surgery, The Second Xiangya Hospital, Central South University) ;
  • Li, Qinglong (Department of General Surgery, The Second Xiangya Hospital, Central South University) ;
  • Xiao, Hua (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Hong, Yuan (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Wang, Xiaohong (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Zhu, Haizhen (Department of Gastroduodenal and Pancreatic Surgery, Translation Medicine Research Center of Liver Cancer, Hunan Province Cancer Hospital and Affiliated Cancer Hospital of Xiangya College) ;
  • Wu, Qunfeng (Department of Pathology, Immunology and Laboratory Medicine and Shands Cancer Center, University of Florida) ;
  • Burns, Michael (Department of Pathology, Immunology and Laboratory Medicine and Shands Cancer Center, University of Florida) ;
  • Liu, Chen (Department of Pathology, Immunology and Laboratory Medicine and Shands Cancer Center, University of Florida)
  • Published : 2015.02.04
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Intrahepatic recurrence is the major cause of death among patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative surgical resection. Several approaches have been reported to decrease the recurrence rate. The objective of our study was to compare the clinical effects of transcatheter arterial chemoembolization (TACE) combined with interferon-alpha (IFN-${\alpha}$) therapy on recurrence after hepatic resection in patients with HBV-related HCC with that of TACE chemotherapy alone. Methods: We retrospectively analyzed the data from 228 patients who were diagnosed with HBV-related HCC and underwent curative resection between January 2001 to December 2008. The patients were divided into TACE (n = 126) and TACE-IFN-${\alpha}$ (n = 102) groups for postoperative chemotherapy. The TACE regimen consisted of 5-fluorouracil (5-FU), cisplatin (DDP), and the emulsion mixed with mitomycin C (MMC) and lipiodol. The recurrence rates, disease-free survival (DFS), overall survival (OS), and risk of recurrence were evaluated. Results: The clinicopathological parameters and adverse effects were similar between the 2 groups (P > 0.05). The median OS for the TACE-IFN-${\alpha}$ group (36.3 months) was significantly longer than that of the TACE group (24.5 months, P < 0.05). The 3-and 5-year OS for the TACE-IFN-${\alpha}$ group were significantly longer than those of the TACE group (P < 0.05) and the recurrence rate was significantly lower (P < 0.05). The TACE and IFN-${\alpha}$ combination therapy, active hepatitis HBV infection, the number of tumor nodules, microvascular invasion, liver cirrhosis, and the BCLC stage were independent predictors of OS and DFS. Conclusions: The use of the TACE and IFN-${\alpha}$ combination chemotherapy after curative hepatic resection safely and effectively improves OS and decreases recurrence in patients with HBV-related HCC who are at high risk. Our findings can serve as a guide for the selection of postoperative adjuvant chemotherapy for patients with HBV-related HCC who are at high risk of recurrence.

Keywords

References

  1. Breunig IM, Shaya FT, Hanna N, et al (2013). Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health, 16, 760-8. https://doi.org/10.1016/j.jval.2013.03.1630
  2. Chun YH, Kim SU, Park JY, et al (2011). Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer, 47, 2568-75. https://doi.org/10.1016/j.ejca.2011.07.002
  3. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. In J Cancer, 127, 2893-917.
  4. Fan ST, Mau Lo C, Poon RT, et al (2011). Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg, 253, 745-58. https://doi.org/10.1097/SLA.0b013e3182111195
  5. Fina RS (2012). Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer, 1, 247-56. https://doi.org/10.1159/000343839
  6. Herzer K, Hofmann TG, Teufel A, et al (2009). IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independenity of p53. Cancer Res, 69, 855-62. https://doi.org/10.1158/0008-5472.CAN-08-2831
  7. Hu L, Xue F, Li Y, et al (2014). A long-term follow-up and comprehensive observation of risk and prognosis factors of recurrence and survival after resection of hepatocellular carcinoma. Cell Biochem Biophys, 69, 421-31. https://doi.org/10.1007/s12013-013-9813-3
  8. Huang G, Lai EC, Lau WY, et al (2013). Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg, 257, 490-505. https://doi.org/10.1097/SLA.0b013e318262b218
  9. Hou J, Zhou Y, Zheng Y, et al (2014). Hepatic RIG-I predicts survival and interferon-$\alpha$ therapeutic response in hepatocellular carcinoma. Cancer Cell, 25, 49-63. https://doi.org/10.1016/j.ccr.2013.11.011
  10. Ippolito D, Bonaffini PA, Ratti L, et al (2010). Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor. World J Gastroenterol, 16, 5993-6000.
  11. Jemal A, Brany F, Center MM, et al (2011). Global cancer statistitics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  12. Jiang W, Zhang C, Tian Z, et al (2013). hIFN-$\alpha$ gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function. Gene Ther, 20, 1062-9. https://doi.org/10.1038/gt.2013.31
  13. Jianyong L, Jinjing Z, Wentao W, et al (2014). Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis. Ann Hepatol, 13, 394-402.
  14. Ji J, Shi J, Budhu A, et al (2009). MicroRNA expression, survival, and response to interferon in liver cancer. N Eng J Med, 361, 1437-47. https://doi.org/10.1056/NEJMoa0901282
  15. Kurth T, Walker AM, Glynn RJ, et al (2006). Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol, 163, 262-70.
  16. Kim KM, Kim JH, Park IS, et al (2009). Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol, 24, 806-14. https://doi.org/10.1111/j.1440-1746.2008.05728.x
  17. Kumamoto T, TanakaK, Matsuo K, et al (2013). Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. Anticancer Res, 33, 5585-90.
  18. Lin S, Hoffmann K, Schemmer P (2012). Treatment of hepatocellular carcinoma review. Liver Cancer, 1, 144-58. https://doi.org/10.1159/000343828
  19. Li KW, Li X, Wen TF, et al (2013). The effect of postoperative TACE on prognosis of HCC: an update. Hepatogastroenterology, 60, 248-51.
  20. Li H, Hu Y, Li N, Zhou Y (2012). Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. Asian Pac J Cancer Prev, 13, 1589-93. https://doi.org/10.7314/APJCP.2012.13.4.1589
  21. Lamm D, Brausi M, O,Donnell MA, et al (2014). Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol, 32, 35.e21-30.
  22. Lai CL, Yuen MF (2013). Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology, 57, 399-408. https://doi.org/10.1002/hep.25937
  23. Li F, Guo Z, Zhang Y, et al (2014). Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study. Ir J Med Sci, 183, 688-90.
  24. Lencioni R (2012). New progress of non-surgical treatments for hepatocellular carcinoma. Semin Oncol, 39, 503-9. https://doi.org/10.1053/j.seminoncol.2012.05.004
  25. Lin LY, Wong VW, Zhou HJ, et al (2010). Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol, 82, 1495-500.
  26. Martin R, Geller D, Espat J, et al (2012). Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepatogastroenterology, 59, 255-60.
  27. Nagano H, Sakon M, Eguchi H, et al (2007). Hepatic resection followed by IFN-$\alpha$ and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology, 54, 172-9.
  28. Poortahmasebi V, Alavian SM, Keyvani H, et al (2014). Hepatic steatosis: prevalence and host/viral risk factors in Iranian patients with chronic hepatitis B infection. Asian Pac J Cancer Prev, 15, 3879-84. https://doi.org/10.7314/APJCP.2014.15.9.3879
  29. Qu LS, Jin F, Huang XW, et al (2010). Interferon-$\alpha$ therapy after Curative resection prevents early recurrence and improves survival in patients with hepatitics B virus-related hepatocellular carcinoma. J Surg Oncol, 102, 796-801. https://doi.org/10.1002/jso.21741
  30. Shen Y, Lin ZZ, Hsu CH, et al (2013). Clinical trials in Hepatocellular carcinoma: An update. Liver Cancer, 2, 345-64. https://doi.org/10.1159/000343850
  31. Sun P, Yang X, He RQ, et al (2013). Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials. Hepatol Res, 44, 259-69.
  32. Sun HC, Tang ZY, Wan L, et al (2006). Postoperative interferon-$\alpha$ treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol, 132, 458-65. https://doi.org/10.1007/s00432-006-0091-y
  33. Sakon M, Nagano H, Dono K, et al (2002). Combination intraarterial 5-Fluorouracil and subcutaneous interferon-$\alpha$ therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer, 2002, 94, 435-42. https://doi.org/10.1002/cncr.10246
  34. Tang ZM, Sun BC (2013). Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol, 19, 8895-901. https://doi.org/10.3748/wjg.v19.i47.8895
  35. Tanaka K, Yabushita Y, Nakagawa K, et al (2013). Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. Eur J Surg Oncol, 39, 1364-70. https://doi.org/10.1016/j.ejso.2013.10.007
  36. Xi T, Lai EC, Min AR, et al (2012). Adjuvant transatheter arterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepatogastroenterology, 59, 1198-203.
  37. Zhong JH, Li LQ (2010). Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res, 40, 943-53. https://doi.org/10.1111/j.1872-034X.2010.00710.x
  38. Zhou YM, Zhang XF, Li B, et al (2014). Prognosis after resection of hepatitis B virus-related hepatocellular carcinoma originating from non-cirrhotic liver. Ann Surg, 21, 2406-12. https://doi.org/10.1245/s10434-014-3505-0

Cited by

  1. Health-Related Quality of Life of Patients with Intermediate Hepatocellular Carcinoma after Liver Resection or Transcatheter Arterial Chemoembolization vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4451
  2. Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5541
  3. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review vol.14, pp.1, 2016, https://doi.org/10.1186/s12957-016-0912-7
  4. Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors vol.96, pp.33, 2017, https://doi.org/10.1097/MD.0000000000007426
  5. Interferon-α Combined With Herbal Compound “Songyou Yin” Effectively Inhibits the Increased Invasiveness and Metastasis by Insufficient Radiofrequency Ablation of Hepatocellular Carcinoma in an Animal Model pp.1552-695X, 2018, https://doi.org/10.1177/1534735418801525